This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-18 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
electron transport chain (ETC) The process by which electrons are transferred from electron donors to electron acceptors via a stepwise series of redox reactions carried out by dedicated enzymes and protein complexes, especially as a component of metabolic pathways which convert chemical energy from food into a form that is readily accessible by the cell. Most electron transport chains begin by oxidizing molecules derived from glycolysis such as NADH and FADH, converting them into a series of intermediate compounds via a specific sequence of independently catalyzed reactions, with the products of the previous reaction used as reactants in the next reaction until ultimately reaching a terminal electron acceptor. The particular compounds used as donors, intermediates, and acceptors vary widely between organisms and cell types; in aerobic respiration, the terminal acceptor is diatomic oxygen (O2), whereas anaerobic respiration uses other acceptors. In all variants, the free energy released by these reactions is coupled to the chemiosmotic pumping of protons (H+) across a membrane in order to generate an electrochemical gradient which is then used to drive the production of ATP, a process known as oxidative phosphorylation. In eukaryotes, electron transport chains are conducted by proteins embedded within the membranes of mitochondria and chloroplasts, while in prokaryotes the relevant proteins are embedded within the cell membrane.
Caution is advised for the use of morphine during pregnancy or breastfeeding, as it may affect the health of the baby. Morphine was first isolated in 1804 by German pharmacist Friedrich Sertürner. This is believed to be the first isolation of a medicinal alkaloid from a plant. Merck began marketing it commercially in 1827. Morphine was more widely used after the invention of the hypodermic syringe in 1853–1855. Sertürner originally named the substance morphium, after the Greek god of dreams, Morpheus, as it has a tendency to cause sleep. The primary source of morphine is isolation from poppy straw of the opium poppy. In 2013, approximately 523 tons of morphine were produced. Approximately 45 tons were used directly for pain, an increase of 400% over the last twenty years. Most use for this purpose was in the developed world. About 70% of morphine is used to make other opioids such as hydromorphone, oxymorphone, and heroin. It is a Schedule II drug in the United States, Class A in the United Kingdom, and Schedule I in Canada. It is on the World Health Organization's List of Essential Medicines. In 2023, it was the 156th most commonly prescribed medication in the United States, with more than 3 million prescriptions. It is available as a generic medication.
=== Veterinary use === Veterinary clinics use cold laser devices to treat a wide variety of ailments, from arthritis to wounds, on dogs and cats. In spite of this, little research has been done on its effects. According to Brennen McKenzie, president of the Evidence-Based Veterinary Medicine Association, as of 2016 "research into cold laser in dogs and cats is sparse and generally low quality. Most studies are small and have minimal or uncertain controls for bias and error". He allowed that some studies show promising results, while concluding that current evidence is not sufficient to support routine clinical use.
GTP = 3′,5′-cyclic GMP + diphosphate It is often part of the G protein signaling cascade that is activated by low intracellular calcium levels and inhibited by high intracellular calcium levels. In response to calcium levels, guanylate cyclase synthesizes cGMP from GTP. cGMP keeps cGMP-gated channels open, allowing for the entry of calcium into the cell. Like cAMP, cGMP is an important second messenger that internalizes the message carried by intercellular messengers such as peptide hormones and nitric oxide and can also function as an autocrine signal. Depending on cell type, it can drive adaptive/developmental changes requiring protein synthesis. In smooth muscle, cGMP is the signal for relaxation, and is coupled to many homeostatic mechanisms including regulation of vasodilation, vocal tone, insulin secretion, and peristalsis. Once formed, cGMP can be degraded by phosphodiesterases, which themselves are under different forms of regulation, depending on the tissue.
23 September – Media outlets, including BBC News, report that a number of firearms officers have stepped back from their role within the Metropolitan Police after a colleague was charged with murder over the shooting of Chris Kaba. Former prime minister Boris Johnson warns present prime minister Rishi Sunak against building what he describes as a "mutilated" version of HS2 following reports that the northern leg of the route from Birmingham to Manchester could be scrapped amid concerns over spiralling costs. 24 September – The Ministry of Defence is offering the Metropolitan Police armed soldiers to support its officers after several firearms officers handed in their weapons. Greater Manchester becomes the first area of England to reverse bus deregulation with the launch of its Bee Network, whereby bus services are franchised by the local authority to bus companies. 25 September – NHS England announces that more than one million appointments and treatments have been lost due to strike action by NHS staff. Mayor of Greater Manchester Andy Burnham says that scrapping the HS2 rail link between Birmingham and Manchester risks "ripping the heart" out of plans to improve rail services across northern England. 27 September – Comer Homes Group is ordered to demolish two tower blocks it built as part of the Mast Quay Phase II complex after Greenwich Borough Council planners determined the blocks differed significantly from the original plans that were submitted and approved in 2012.
Sources: en.wikipedia.org
Chiral recognition implies the ability of chiral stationery phases to interact differently with mirror-image molecules, leading to their separation. The mechanism of enantiomeric resolution using CSPs is generally attributed to the "three-point" interaction model (fig.1.) between the analyte and the chiral selector in the stationary phase. Also known as the Dalgliesh model. Under this model, for chiral recognition, and hence enantiomeric resolution to happen on a CSP one of the enantiomers of the analyte must be involved in three simultaneous interactions. This means to say the one of enantiomers is able to have a good interaction with the complimentary sites on the chiral selector attached to the CSP. While Its mirror-image partner may only interact at two or one such sites. In the figure, enantiomer (a), has the correct configuration of the ligands (X, Y and Z) for three-point interactions with the complimentary sites (X', Y' and Z') on the CSP, while its mirror image (b) can only interact at one site. The dotted lines (-----) indicate interaction with complimentary sites. The diastereomeric complexes thus formed will have different energies of interaction. The enantiomer forming the more stable complex will have less energy and stay longer in the stationary phase compared to the less stable complex with higher energy. The success of chiral separation basically depends in manipulating the subtle energy differences between the reversibly formed non-covalent transient diastereomeric complexes. The energy difference reflects the magnitude of enantioselectivity.
The hydrolysis that elastases bring about occur in several steps, starting with the formation of a complex between elastase and its substrate, with the carbonyl carbon positioned near the nucleophilic serine, followed by a nucleophillic attack that forms an acyl-enzyme intermediate (a pair of electrons from the double bond of the carbonyl oxygen moves to the oxygen) while the first product is released. The intermediate is then hydrolyzed in a deacylation step, regenerating the active enzyme and resulting in the release of the second product ( the electron-deficient carbonyl carbon re-forms the double bond with the oxygen and the C-terminus of the peptide is released. It preferentially cleaves peptide bonds at the carbonyl end of amino acid residues with small hydrophobic side chains such as glycine, valine, leucine, isoleucine and alanine. The wide specificity of elastases for non-aromatic uncharged side chains can explain its ability to break down native elastin.
If the outlet CO2 is captured, it can be re-compressed and recycled, allowing for >90% reuse of CO2. Similar to HPLC, SFC uses a variety of detection methods including UV/VIS, mass spectrometry, FID (unlike HPLC) and evaporative light scattering.
Following a single oral dose of 420 mg EMP in men with prostate cancer, maximal levels of estromustine were 310 to 475 ng/mL (475,000 pg/mL) and occurred after 2 to 3 hours. Estradiol levels with 280 mg/day oral EMP have been found to increase to very high concentrations within one week of therapy. In one study, levels of estradiol were over 20,000 pg/mL after 10 days, were about 30,000 pg/mL after 30 days, and peaked at about 40,000 pg/mL at 50 days. Another study found lower estradiol levels of 4,900 to 9,000 pg/mL during chronic therapy with 560 mg/day oral EMP. An additional study found estradiol levels of about 17,000 pg/mL with 140 mg/day oral EMP and 38,000 pg/mL with 280 mg/day oral EMP. The circulating levels of estradiol and estrone during EMP therapy have been reported to exceed normal levels in men by more than 100- and 1,000-fold, respectively. Levels of estramustine and estradiol in the circulation are markedly lower than those of estromustine and estrone, respectively, with a ratio of about 1:10 in both cases. Nonetheless, estradiol levels during EMP therapy appear to be similar to those that occur in mid-to-late pregnancy, which range from 5,000 to 40,000 pg/mL. No unchanged EMP is seen in the circulation with oral administration. The pharmacokinetics of EMP are different with intravenous injection. Following a single intravenous injection of 300 mg EMP, levels of EMP were higher than those of its metabolites for the first 8 hours. This is likely due to the bypassing of first-pass metabolism.
== Music and lyrics == Guitarist-vocalist Bill Steer retrospectively said that "The first album wasn’t very focused, it was just about being fast and heavy..." He went on to say that the band did not intend the muddy sound present throughout the album: "The first one obviously is a crazy accident. It’s got a small following but we did not intend to make that record the thing that people hear now. We had different ideas and we just couldn’t execute them. We were too young, too naïve, and inexperienced. From 'Symphonies' onwards, we got better at achieving the things we wanted to achieve in the studio." Revolver said that the album's music was "hectic, brutal and sounds like it was recorded beneath a stack of wet mattresses." Invisible Oranges wrote: "Carcass’ 1988 [debut] set new standards for auditory dismemberment, channeling the sound of Napalm Death through a vomited, gore-encrusted wormhole backwards. This is the aural nightmare of the dissecting table pushed beyond the extremes previously explored by the tinny sounds of blackthrash with bowl-rupturing, gurgling low end. Ken Owen flails about so nightmarishly you can’t even really distinguish if he’s even playing drums or has merely taken the contents of mortician’s tools of the trade and thrown them out of the window of morgue into the biohazard-labeled dumpster." Lyrical themes explored on the album include vomitting, feces, wound healing, and foeticide. According to Revolver, the track "Foeticide" is a "horrific description of abortion by electrocution [...] a mad scientist frying human babies in their wombs."
Sources: en.wikipedia.org
This does not replace the refrigeration system but facilitates cooling down of the external machinery. Containers stowed on the exposed upper deck are air-cooled, while those under deck are water-cooled. The water cooling design allows additional refrigerated containers under deck, as water can be used to dissipate the high amount of heat they generate. This system draws fresh water from the ship's water supply, which in turn transfers the heat through heat exchangers to the abundantly available sea water.
organized criminal: structured group, three or more people, one or more serious crimes, in order to obtain financial or other material benefit; serious crime: offense punishable by at least four years in prison; and, structured group: Not randomly formed but does not need formal structure, Others stress the importance of power, profit and perpetuity, defining organized criminal behavior as:
Karen M. Frank is an American clinical pathologist and microbiologist researching the pathogenesis of Staphylococcus aureus pneumonia and resistant gram-negative bacteria. She is a senior clinician, principal investigator, and chief of laboratory medicine at the National Institutes of Health Clinical Center.
=== Other === Photon correlation spectroscopy/Dynamic light scattering (DLS) Terahertz spectroscopy (THz) Electron paramagnetic/spin resonance (EPR, ESR) Small-angle neutron scattering (SANS) Rutherford backscattering spectrometry (RBS) Spatially resolved acoustic spectroscopy (SRAS)
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.